



CLAIMS

1. Use of a non-immunosuppressive, cyclophilin-binding cyclosporin in the manufacture of a medicament for treating or preventing ischemic brain damage , traumatic brain or spinal cord injury or stroke.
2. A method for the treatment or the prevention of ischemic brain damage or traumatic brain or spinal cord injury in a patient suffering from or at risk of suffering from such a disease or condition, comprising administering to said patient an effective amount of a non-immunosuppressive, cyclophilin-binding cyclosporin.
3. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppressive, cyclophilin-binding cyclosporin is a compound of formula (A):



wherein B is an amino acid residue of formula (B):



wherein

a denotes the bond to the α Abu residue in position 2;

b denotes the bond to the residue C in the 4 position;

Alk represents straight- or branched-chain alkylene containing from 2-6 carbon atoms or cycloalkylene containing from 3-6 carbon atoms; and

R represents

a carboxy or alkyloxycarbonyl radical;


a radical $\text{-NR}_1\text{R}_2$,

in which

R_1 and R_2 are the same or different and represent hydrogen, alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, phenyl (optionally substituted by halogen, alkoxy, alkoxy carbonyl, amino, alkylamino or dialkylamino) or a benzyl or saturated or unsaturated heterocyclyl radical containing 5- or 6-ring atoms and 1-3 heteroatoms, or

R_1 and R_2 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4-6 ring atoms and optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur and optionally substituted by alkyl, phenyl or benzyl;

a radical of formula:



wherein

R_1 and R_2 are as defined above;

R_3 represents hydrogen or an alkyl radical; and


n is a whole number from 2-4; and

alkyl denotes straight- or branched-chain alkyl containing from 1-4 carbon atoms;

C is MeLeu or 4-hydroxy-MeLeu;

and the pharmaceutically acceptable salts thereof.

4. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppressive, cyclophilin-binding cyclosporin is a compound of formula (I):



in which

W is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;

X is α Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Sar or (D)-MeAla;

Y is MeLeu, γ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Me Tyr, MeTyr(O-PO(OH)₂), Mealle or MeaThr or Pro;

Z is Val, Leu, *N*-Alk-Val or *N*-Alk-Leu, wherein Alk represents Me or Me substituted by vinyl optionally substituted by phenyl, or an N, S or O heteroaryl containing 6 ring members, or phenyl optionally substituted by halogen; and

Q is MeLeu, γ -hydroxy-MeLeu or MeAla.

5. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppressive, cyclophilin-binding cyclosporin is a compound selected from the group comprising:

- a) [dihydro-MeBmt]¹-[γ -hydroxy-MeLeu]⁴-Ciclosporin;
- b) [MeVal]⁴-Ciclosporin;
- c) [Melle]⁴-Ciclosporin;
- d) [MeThr]⁴-Ciclosporin;
- e) [γ -hydroxy-MeLeu]⁴-Ciclosporin;
- f) [Nva]²-[γ -hydroxy-MeLeu]⁴-Ciclosporin;
- g) [γ -hydroxy-MeLeu]⁴-[γ -hydroxy-MeLeu]⁶-Ciclosporin;
- h) [MeVal]⁵-Ciclosporin;
- i) [MeOThr]²-[(*D*)MeAla]³-[MeVal]⁵-Ciclosporin;
- j) [8'-hydroxy-MeBmt]¹-Ciclosporin;
- k) [MeAla]⁶-Ciclosporin;
- l) [DMeAla]³-[MeTyr(OPO(OH)₂)]⁴-Ciclosporin;
- m) [*N*-Benzyl-Val]⁵-Ciclosporin;
- n) [*N*-5-Fluoro-Benzyl-Val]⁵-Ciclosporin;
- o) [*N*-Allyl-Val]⁵-Ciclosporin;
- p) [*N*-3-Phenyl-Allyl-Val]⁵-Ciclosporin;
- q) [Pro]⁴-Ciclosporin or
- r) [γ -hydroxy-MeLeu]⁹-Ciclosporin.

6. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppressive, cyclophilin-binding cyclosporin is [Melle]⁴-Ciclosporin or [γ -hydroxy-MeLeu]⁴-Ciclosporin.